Board of Directors

Last modified: 18.6.2020

Board of Directors

Pursuant to the company’s Articles of Association, the Board of Directors shall comprise of a minimum of 5 and a maximum of 8 members. The Annual General Meeting elects the members of the Board of Directors. The term of office of the members of the Board of Directors will expire at the end of the next Annual General Meeting following the election.

The Board of Directors has general competence to decide and act in all matters not reserved for other corporate governing bodies by law or under the provisions of the company’s Articles of Association. The Board of Directors is responsible for the company’s administration and the appropriate organisation of its operations. The Board of Directors decides on company and group wide significant matters of principal importance. The Board of Directors appoints and dismisses the CEO, supervises his or her actions and decides on his or her remuneration and other terms and conditions of employment. The Board of Directors also makes decisions on the strategy, key investments, organisation and financial affairs of the company. In addition, the Board of Directors monitors and assesses the company’s financial performance and position and reviews and approves the company’s interim reports and financial statements. In all situations, the Board of Directors must act in accordance with the best interest of the company.

 

Petri Salonen

B. 1958, Finnish citizen
Chairman of the Board of Directors since 2006
Dependent of the company

Petri Salonen serves as the Chairman of the Board of Directors of Delfoi Ltd and as a member of the Boards of Director of AW-Energy Oy. In addition, he serves as Sales Director at JAS Partners Oy. Previously, Mr. Salonen was the Chairman and a member of the Board of Directors of Commit; Oy (presently Optomed Software Oy), a member of the Boards of Directors of Aura Capital Oy, Chip-Man Technologies Ltd, IonPhasE Ltd and Silicon Laboratories Finland Inc, the Chief Executive Officer of Atbusiness Communications Oyj and Bluegiga Technologies Inc. and the Investment Director of Aura Capital Oy. Petri Salonen is dependent of the company as he has had consultancy agreement with the company and receives salary. Further, he has been a member of the Board for more than 10 years.

Education: Master of Science degree in Shipbuilding Technology, Naval Architecture and Marine Engineering from Aalto University.

 

Seppo Mäkinen

B. 1952, Finnish citizen
Member of the Board of Directors since 2019
Independent of the company and major shareholders

Seppo Mäkinen serves as a member of the Boards of Directors of Bittium Corporation, AegirBio AB and Videovisit Ltd, as a deputy member of the Board of Directors of Noribe Group Oy and Taikon Advisor Oy. Previously, Mr. Mäkinen was the Chairman of the Boards of Directors of Taikon Advisor Oy and ValiFinn Ltd, and a member of the Board of Directors of Neurotar Ltd, ArcDia International Oy Ltd, Coimbra Genomics SA, Evondos ltd, Ginolis Oy, Magnasense Technologies Oy, Med Group Oy, Med Group Holding Oy and Valirx Oy. In addition, he has been Partner at Ventac Partners, partner at Pathena SGPS, and Regional Partner at Mérieux Développement SAS, Founding and Managing Partner at BioFund Ventures and Director of Life Sciences at Sitra.

Education: Master of Science degree in Physical Chemistry from the University of Jyväskylä.

 

Reijo Tauriainen

B. 1956, Finnish citizen
Member of the Board of Directors since 2019
Independent of the company and major shareholders

Reijo Tauriainen serves as the Chairman of the Boards of Directors of Arvo Invest Nordic Oy, Meka Pro Oy, Pohjanmaan Arvo Sijoitusosuuskunta and Unipro Oy Ltd, as a member of the Boards of Directors of Champion Door Oy, Hoivatilat Plc, Lapwall Oy, Nordic Option Oy, Propria Oy, Temotek Oy and Temotek Palvelut Oy. Previously, Mr. Tauriainen was the Chairman of the Boards of Directors of Nordic Option Oy, Oulun Ydinkeskustan Parkki Oy, Sanerall Group Oy, Technopolis Kiinteistöt Pääkaupunkiseutu Oy, Technopolis Kiinteistöt Oulu Oy and Technopolis Kiinteistöt Tampere Oy, the Chief Executive Officer of Pohjanmaan Arvo Sijoitusosuuskunta, and a member of the Board of Directors and the Chief Financial Officer of Uros Ltd and as the Deputy Chief Executive Officer and Chief Financial Officer of Technopolis Plc. In addition, he has served as a member of the Board of Directors of Technopolis Kuopio Oy, as a deputy member of the Board of Directors and the Chief Executive Officer of Technopolis Hitech Oy.

Education: Master of Science degree in Economics from the University of Oulu.

 

Anna Tenstam

B. 1964, Swedish citizen
Member of the Board of Directors since 2020
Independent of the company

Anna Tenstam serves as the Chairman of Board of Directors of Sue Ellen Investments AB,  the co-founder and Chairman of Board of Directors of Agamé Beauty AB and Estelle Medical AB, the Chairman of Board of Directors and partner of Expomind AB. Previously, Ms Tenstam has been the Chairman of the Board of Directors of Betagenon Ab, Patients Pending Ltd as well as the CEO and the Chairman of the Board of Eternogen LLC.

Education: Master of Science at Uppsala University, an MBA from IMD Business School, EMP at Stockholm School of Business.

 

Jun Wu

B. 1966, United States citizen
Member of the Board of Directors since 2014
Dependent of a major shareholder

Jun Wu is the founder, Chairman and Managing Partner of Cenova Capital and serves as a member of the Boards of Directors of Aslan Pharmaceuticals Ltd, Cheng Heng Health Science and Technology Holdings Ltd, Choice Technology Inc, Etongonline Shanghai Medical Consulting Co. Ltd, HK Doctorlink Internet Tech Co. Ltd, Jing Medicine Technology (Shanghai) Ltd, Luqa Ventures Co. Ltd, Shanghai Aohua Photoelectricity Endoscope Co., Shanghai EnsurLink Ltd, Shanghai Lianji Biotechnology Co. Ltd, Shanghai Yao Shi Quan Cloud Health Technology Development Ltd, Start (Shanghai) Pharmaceutical Technology Ltd, Suzhou SceneRay Corporation Ltd, Virtuoso Therapeutics Inc and Vivace Therapeutics Inc. In addition, he serves as a Director at Alnair Investment, Cenova China Healthcare GP IV Ltd, Cenova Management Advisors Ltd, Novoasis Investment Ltd and Ruikang Investment Ltd. Furthermore, Mr. Wu is the co-founder of Shanghai Genomics, Inc. and he has previously served as the Chief Executive Officer, as a member of the Board of Directors and held various managerial postions at Shanghai Genomics, Inc., as well as various managerial positions at GNI Ltd. He is dependent of a major shareholder of the company due to him controlling a major shareholder.

Education: Doctor of Philosophy degree in Microbiology and Immunology from the University of California at San Francisco and a Bachelor of Science degree in Biology from San Jose State University.